Osteoprotegerin expression on aortic atherosclerotic plaques and vessel calcification of diabetes mellitus rats

doi:10.3969/j.issn.1673-8640.2017.04.020

Abstract

Abstract:

Objective To investigate the expression of osteoprotegerin（OPG） on aortic atherosclerotic plaques and vascular calcification of diabetes mellitus rats and the interference of pioglitazone. Methods A total of healthy male SD rats were enrolled and classified into 6 groups randomly,and there were 7 rats in each group,including control group （group A）,diabetes mellitus group（group B）,aortic atherosclerotic plaque and vessel calcification group（group C）,diabetes mellitus+aortic atherosclerotic plaque and vessel calcification group（group D）,aortic atherosclerotic plaque and vessel calcification+pioglitazone group（group E） ,diabetes mellitus+aortic atherosclerotic plaque and vessel calcification+pioglitazone group（group F）. Blood was extracted from rats on the 30th day for the determinations of high-sensitivity C-reactive protein（hs-CRP）,fasting plasma glucose（FPG）,glycated hemoglobin A _1c（HbA_1c）and OPG. Calcium deposits in thoracic aorta and alkaline phosphatase（ALP） activity were determined. Results The success rate of diabetes mellitus rat modeling was 100%. Compared with group A,the levels of calcium deposits in thoracic aorta,ALP activities,OPG and hs-CRP in group C,D and E increased（P<0.05）. The levels of calcium deposits in thoracic aorta and ALP activities increased（P<0.05）,and there was no statistical significance for hs-CRP and OPG in group F（P>0.05）. The levels of calcium deposits in thoracic aorta,ALP activities and OPG had statistical significance between group C and E（P<0.05）. The levels of ALP activities,hs-CRP,FPG,HbA_1c and OPG between group D and F were statistically significant（P<0.05）. The levels of calcium deposits in thoracic aorta and OPG in group F were lower than those in group E（P<0.05）. OPG was positively related with the levels of calcium deposits in thoracic aorta,ALP activities and hs-CRP and FPG（r=0.654,0.218,0.539 and 0.711,P<0.05 or P<0.01）. Conclusions Pioglitazone can reduce the formation of aortic atherosclerotic plaques and vessel calcification,and the mechanism might be related to the regulation of OPG,the inhibition of inflammatory reaction and the decreasing of calcium salt deposition.

Key words: Osteoprotegerin, Atherosclerosis, Diabetes mellitus, Vessel calcification

CLC Number:

R446.1

SUN Yefu, CHEN Guiming, XIA Aiping, ZHANG Zhifeng. Osteoprotegerin expression on aortic atherosclerotic plaques and vessel calcification of diabetes mellitus rats[J]. Laboratory Medicine, 2017, 32(4): 333-337.

Figures/Tables 1

References 27

[1]	Task Force on Diabetes,Pre-diabetes,and Cardiovascular Diseases of the European Society of Cardiology,European Association for the Study of Diabetes,RYDéN L,et al.ESC guidelines on diabetes,pre-diabetes,and cardiovascular diseases developed in collaboration with the EASD-summary[J]. Diab Vasc Dis Res,2014,11(3):133-173.
[2]	周小莉,林尤斌,王斐,等.2型糖尿病患者并发动脉粥样硬化的影响因素分析[J].实用心脑肺血管病杂志,2016,24(2):155-157.
[3]	WILDING J P.PPAR agonists for the treatment of cardiovascular disease in patients with diabetes[J].Diabetes Obes Metab,2012,14(11):973-982.
[4]	陈桂明,孙业富,夏爱萍,等.2型糖尿病并发骨质疏松病变患者血清OPG及C-反应蛋白与尿微量清蛋白/肌酐比值的关系[J].国际检验医学杂志,2016,37(1):87-89.
[5]	MASER R E,LENHARD M J,SNEIDER M B,et al.Osteoprotegerin is a better serum biomarker of coronary artery calcification than osteocalcin in type 2 diabetes[J]. Endocr Pract,2015,21(1):14-22.
[6]	王园园,龙民慧,邹民吉,等.大鼠动脉粥样硬化动物模型的建立和评价[J]. 中国实验动物学报,2008,16(6):421-423.
[7]	周永刚,蓝晓红,李祥,等.动脉粥样硬化大鼠实验模型的建立与评价[J]. 解放军药学学报,2011,27(5):399-403.
[8]	李同达,曹洪欣,徐慧,等.冠状动脉粥样硬化大鼠实验动物模型的改进与评价[J]. 中国实验动物学报,2013,21(6):32-36.
[9]	王竹,杨月欣,向雪松,等.实验大鼠血糖正常范围的估算[J]. 卫生研究,2010,39(2):133-137.
[10]	中华人民共和国科学技术部. 关于善待实验动物的指导性意见[Z].2006-09-30.
[11]	GONG Z,XING S,ZHENG F,et al.Increased expression of macrophage migration inhibitory factor in aorta of patients with coronary atherosclerosis[J]. J Cardiovasc Surg (Torino),2015,56(4):631-637.
[12]	皮银珍,杨腾舜,莫娟,等.糖尿病慢性并发症患者护骨素水平分布及调脂干预研究[J]. 湖南师范大学学报(医学版),2014,11(4):18-20.
[13]	SAITO I,KOKUBO Y,YAMAGISHI K,et al.Diabetes and the risk of coronary heart disease in the general Japanese population: the Japan Public Health Center-based prospective (JPHC) study[J].Atherosclerosis,2011,216(1):187-191.
[14]	SUGAWARA A,URUNO A,KUDO M,et al.Effects of PPARγ on hypertension,atherosclerosis,and chronic kidney disease[J]. Endocr J,2010,57(10):847-852.
[15]	ARMSTRONG Z B,BOUGHNER D R,DRANGOVA M A,et al.Angiotensin Ⅱ type 1 receptor blocker inhibits arterial calcification in a pre-clinical model[J]. Cardiovasc Res,2011,90(1):165-170.
[16]	KARWOWSKI W,NAUMNIK B,SZCZEPA SKI M,et al . The mechanism of vascular calci-fication-a systematic review[J]. Med Sci Monit,2012,18(1):RA1-RA11.
[17]	SIMONET W S,LACEY D L,DUNSTAN C R,et al.Osteoprotegerin:a novel secreted protein involved in the regulation of bone density[J]. Cell,1997,89(2):309-319.
[18]	杨立顺,袁海生,沈兴娅,等. 绝经后骨质疏松症相关骨代谢指标的分析[J]. 检验医学,2013,28(8):685-689.
[19]	PéREZ DE CIRIZA C,LAWRIE A,VARO N. Osteoprotegerin in Cardiometabolic Disorders[J]. Int J Endocrinol,2015,2015:564934.
[20]	BUMDELGER B,KOKUBO H,KAMATA R,et al.Osteoprotegerin prevents development of abdominal aortic aneurysms[J]. PLoS One,2016,11(1):e0147088.
[21]	MAKAROVI S,MAKAROVI Z,STEINER R,et al.Osteoprotegerin and vascular calcification: clinical and prognostic relevance[J]. Coll Antropol,2015,39(2):461-468.
[22]	WANG F,LERMAN A,HERRMANN J.Dysfunction of the ubiquitin-proteasome system in atherosclerotic cardiovascular disease[J]. Am J Cardiovasc Dis,2015,5(1): 83-100.
[23]	MASER R E,LENHARD M J,SNEIDER M B,et al.Osteoprotegerin is a better serum biomarker of coronary artery calcification than osteocalcin in type 2 diabetes[J]. Endocr Pract,2015,21(1):14-22.
[24]	OZKOK A,CALISKAN Y,SAKACI T,et al.Osteoprotegerin/RANKL axis and progression of coronary artery calcification in hemodialysis patients[J]. Clin J Am Soc Nephrol,2012,7(6):965-973.
[25]	BJERRE M.Osteoprotegerin(OPG) as a biomarker for diabetic cardiovascular complica-tions[J].Springerplus,2013,2:658.
[26]	WANG S T,ZHANG C Y,ZHANG C M,et al.The plasma osteoprotegerin level and osteo-protegerin expression in renal biopsy tissue are increased in type 2 diabetes with nephrop-athy[J]. Exp Clin Endocrinol Diabetes,2015,123(2):106-111.
[27]	KIM J Y,PARK Y J,KIM K J,et al.Osteoprotegerin causes apoptosis of endothelial progenitor cells by induction of oxidative stress[J].Arthritis Rheum,2013,65(8):2172-2182.

组别	例数	hs-CRP（mmol/L）	FPG（mmol/L）	HbA_1c（%）	钙（μmol/L）	ALP（IU/L）	OPG （ng/L）
A组	7	25.39±12.21	5.05±1.14	4.17±0.85	18.15±1.47	19.03±1.46	2.17±0.36
B组	7	32.25±9.32	18.63±4.55^*	24.89±4.52^*	22.25±4.30	28.25±5.34	3.42±0.39
C组	7	188.67±65.16^*	8.42±2.19	6.79±1.13	58.25±16.17^*	79.25±8.22^*	4.79±0.65^*
D组	5	219.31±80.95^*	22.75±5.16^*	26.62±6.29^*	76.11±19.87^*	101.25±7.06^*	5.62±0.99^*
E组	7	36.52±19.26^*#△	6.25±1.94^△	6.04±1.17^△	33.53±9.39^*#△	83.11±9.52^*#△	3.94±0.55^*#△
F组	6	32.77±16.43^△	6.78±2.77^*△	6.73±1.39^*△	27.31±6.55^*△▲	72.44±5.38^*△	2.79±0.41^△▲

组别	例数	hs-CRP（mmol/L）	FPG（mmol/L）	HbA_1c（%）	钙（μmol/L）	ALP（IU/L）	OPG （ng/L）
A组	7	25.39±12.21	5.05±1.14	4.17±0.85	18.15±1.47	19.03±1.46	2.17±0.36
B组	7	32.25±9.32	18.63±4.55^*	24.89±4.52^*	22.25±4.30	28.25±5.34	3.42±0.39
C组	7	188.67±65.16^*	8.42±2.19	6.79±1.13	58.25±16.17^*	79.25±8.22^*	4.79±0.65^*
D组	5	219.31±80.95^*	22.75±5.16^*	26.62±6.29^*	76.11±19.87^*	101.25±7.06^*	5.62±0.99^*
E组	7	36.52±19.26^*#△	6.25±1.94^△	6.04±1.17^△	33.53±9.39^*#△	83.11±9.52^*#△	3.94±0.55^*#△
F组	6	32.77±16.43^△	6.78±2.77^*△	6.73±1.39^*△	27.31±6.55^*△▲	72.44±5.38^*△	2.79±0.41^△▲